NEW YORK (GenomeWeb News) — Cepheid and BioMerieux plan to develop and market a line of sepsis tests, the companies said today.
The companies said they will develop assays to identify fungi and bacteria and genetic markers for antibiotic resistance. Cepheid and BioMerieux also said that the panel could be used to identify hospital-acquired pneumonia.
The tests will work on Cepheid’s GeneXpert platform. Cepheid will manufacture them and BioMerieux will distribute them worldwide.
As part of the deal, BioMerieux has licensed Cepheid patents for its methicillin-resistant Staphylococcus aureus test. Cepheid will continue to develop, manufacture, and market the products
Financial terms of the agreement were not released.
Sepsis is a bacterial infection of the bloodstream that affects a small percentage of hospital patients, generally those with depressed immune systems. The condition affects around 750,000 Americans each year and results in death in between a quarter and a half of them. US hospitals $17 billion a year treating the infections, the companies said.
Cepheid CEO John Bishop said a rapid sepsis test coupled with a “molecular snapshot of drug-resistant organisms” will allow doctors to make better treatment decisions more quickly.